introduction: tyrosine kinase inhibitors (tkis) were the first drugs to use an intracellular signaling molecule as a therapeutic target. unresponsiveness to tkis limits therapeutic options, making allogeneic hematopoietic stem cell transplantation (hsct) the only option leading to molecular remission. objectives: to characterize cml patients unresponsive to first- and/or second-generation tki t...

lung cancer is still diagnosed in advanced stage and most patients do not have the opportunity for surgical treatment. although in the recent years new diagnostic equipment is available such as the radial and linear endobronchial ultrasound (ebus) and electromagnetic fiberoptic bronchoscopy. however; novel targeted therapies with tyrosine kinase inhibitors of second generation and immunotherapy...

x-linked agammaglobulinemia (xla) is an immunodeficiency caused by mutations in the bruton tyrosine kinase (btk) gene. in order to identify the mutations in btk gene in iranian patients with antibody deficiency, 13 male patients with an xla phenotype from 11 unrelated families were enrolled as the subjects of investigation for btk mutation analysis using pcr-sscp followed by sequencing. five di...

mpns including a heterogeneous group of clonal or oligoclonal hamtopathies characterized by proliferation and accumulation of mature myeloid cells. jak2 tyrosine kinase mutation is the most common molecular lesion identified in 90% of cases. jak2 is involved in epo signaling pathway, and mutations in it lead to epo-independent spontaneous phosphorylation. most tyrosine kinase inhibitors (tki) a...

MPNs including a heterogeneous group of clonal or oligoclonal hamtopathies characterized by proliferation and accumulation of mature myeloid cells. JAK2 tyrosine kinase mutation is the most common molecular lesion identified in 90% of cases. JAK2 is involved in EPO signaling pathway, and mutations in it lead to EPO-independent spontaneous phosphorylation. Most tyrosine kinase inhibitors (TKI) a...

Tyrosine kinase inhibitors (TKIs) are the mainstay of current management chronic myeloid leukemia (CML) [1]. With introduction imatinib, many CML patients in phase (CML-CP) we...

FMS-like tyrosine kinase-3 is a receptor tyrosine kinase expressed by immature hematopoietic cells and is important for the normal development of stem cells and the immune system. Mutations of FMS-like tyrosine kinase-3 have been detected in about 30% of patients with acute myelogenous leukemia and a small number of patients with acute lymphoblastic leukemia. The FMS-like tyrosine kinase-3 muta...

background :according to numerous studies, fms-like tyrosine kinase 3, internal tandem duplication, and the d835 mutation are associated with a poor prognostic clinical outcome in acute myeloid leukemia patients. detection of the fms-like tyrosine kinase 3 mutation in patients who present with normal karyotype acute myeloid leukemia helps in both the understanding of the disease and the treatme...

By targeting both arms of the immune system, not just B cells, brain-penetrant inhibitors Bruton’s tyrosine kinase could improve on anti-CD20 therapy for patients with multiple sclerosis.